Outcomes in patients with small node‐negative invasive breast cancer

There is controversy whether systemic therapy is warranted in patients with small node‐negative tumors, especially among those with HER2+ and triple negative breast cancers (TNBC). In this study we sought to compare survival and recurrence rates (RR) in patients with T1mi,a,bN0M0 breast cancer by tumor type.

[1]  Jeong Eon Lee,et al.  A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? , 2010, Breast Cancer Research and Treatment.

[2]  G. Hortobagyi,et al.  Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Loda,et al.  Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome. , 1997, Cancer.

[4]  L. Habel,et al.  Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[6]  T. Ignatov,et al.  Management of small T1a/b breast cancer by tumor subtype , 2017, Senologie - Zeitschrift für Mammadiagnostik und -therapie.

[7]  D. Noh,et al.  Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less , 2010, BMC Cancer.

[8]  K. Bilimoria,et al.  Treatment Trends and Factors Associated with Survival in T1aN0 and T1bN0 Breast Cancer Patients , 2007, Annals of Surgical Oncology.

[9]  L. Livi,et al.  Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node‐negative breast cancer , 2012, Cancer.

[10]  E. Winer,et al.  Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Vincent-Salomon,et al.  Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  K. Boachie‐Adjei,et al.  Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study , 2013, Breast Cancer Research and Treatment.

[13]  P. Saigo,et al.  Predictors of recurrence in stage I (T1N0M0) breast carcinoma. , 1981, Annals of surgery.

[14]  R. Kreienberg,et al.  Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients , 2016, Archives of Gynecology and Obstetrics.

[15]  S. Chia,et al.  Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Sikov,et al.  Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: application and outcomes. , 2013, Breast.

[17]  C. Hudis,et al.  Favorable prognosis in patients with T1a/T1bN0 triple‐negative breast cancers treated with multimodality therapy , 2012, Cancer.

[18]  N. Harbeck,et al.  Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry. , 2015, Breast.

[19]  A. Goldhirsch,et al.  Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Wolmark,et al.  Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. , 2001, Journal of the National Cancer Institute.

[21]  A. Luini,et al.  Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes , 2011, Breast Cancer Research and Treatment.

[22]  F. Cardoso,et al.  Small breast cancers: when and how to treat. , 2014, Cancer treatment reviews.

[23]  Funda Meric-Bernstam,et al.  High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Z. Tong,et al.  Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer. , 2012, Japanese journal of clinical oncology.